Affinity Asset Advisors »

Karyopharm Therapeutics Inc note 3.000%10/1 shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Karyopharm Therapeutics Inc note 3.000%10/1 shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Karyopharm Therapeutics Inc note 3.000%10/1

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics Inc note 3.000%10/1 held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics Inc note 3.000%10/1 by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $6.3M 9.8M 0.65

More positions owned by Affinity Asset Advisors

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Madrigal Pharmaceuticals (MDGL)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Celldex Therapeutics Com New (CLDX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Alnylam Pharmaceuticals Note 1.000% 9/1 (Principal)
Beigene Sponsored Adr (BGNE)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)

View all positions for Affinity Asset Advisors

Top funds holding Karyopharm Therapeutics Inc note 3.000%10/1

Affinity Asset Advisors
Opaleye Management
Capstone Investment Advisors
BLB^B Advisors
Jpmorgan Chase & Co

View all funds holding Karyopharm Therapeutics Inc note 3.000%10/1